Erschienen in:
01.05.2010
Naturally Occurring IgM Anti-Leukocyte Autoantibodies Inhibit T-Cell Activation and Chemotaxis
verfasst von:
Peter I. Lobo, Kailo H. Schlegal, John Vengal, Mark D. Okusa, Hong Pei
Erschienen in:
Journal of Clinical Immunology
|
Sonderheft 1/2010
Einloggen, um Zugang zu erhalten
Abstract
Introduction
Naturally occurring IgM antileukocyte antoantibodies (IgM-ALA) are present from birth and increase during inflammatory processes of diverse etiologies. The clinical observation demonstrating a significant correlation (P < 01) between lack of acute rejections and presence of high levels of IgM-ALA in recipients of kidney allografts prompted us to study if IgM-ALA alters T-cell function and leukocyte chemotaxis.
Methods
In-vitro functional assays were performed using leucocytes isolated from human peripheral blood. In-vivo studies were performed in C57BL6 mice.
Result
Human studies revealed that IgM-ALA consist of several different IgM, each with specificities for a different leukocyte receptor, e.g., CD3, CD4, CCR5, and CXCR4. We show that IgM inhibits T-cell activation, proliferation, and chemotaxis. Data on in vivo murine models of ischemia-reperfusion injury and cardiac transplantation support our hypothesis.
Conclusion
The innate anti-inflammatory mechanism of IgM-ALA can be exploited by using purified normal IgM to inhibit inflammatory states or by a vaccine approach to increase in vivo production of IgM-ALA (e.g., prior to a transplant).